Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmacia & Upjohn

This article was originally published in The Tan Sheet

Executive Summary

Nicorette sales were up 9.6% in 1999, totaling $233.6 mil., but declined 7.1% in the fourth quarter to $61.1 mil. due to strong year-ago sales that resulted from the introduction of the product's mint flavor. P&U directly sells the smoking cessation gum in various international markets and under a licensing agreement with SmithKline Beecham in the U.S. Firm's net sales increased 11.9% to $7.18 bil. for the year, while fourth quarter sales rose 9.7% to $1.94 bil. Net earnings - after adjusting for the acquisition of SUGEN, Inc. and various R&D charges - reached $944 mil. for the year, up 13.6%, and climbed 11.1% to $261 mil. in the quarter. The company announced Dec. 19 its plans to merge with Monsanto; the deal is expected to close in the first half of the year

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel